Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imsidolimab - AnaptysBio

Next Previous
Drug Profile

Imsidolimab - AnaptysBio

Alternative Names: ANB 019

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pustular psoriasis

Highest Development Phases

  • Phase III Generalised pustular psoriasis
  • Phase II Acneiform eruptions; Ichthyosis
  • No development reported Palmoplantar pustulosis
  • Discontinued Acne vulgaris; Hidradenitis suppurativa

Most Recent Events

  • 05 May 2025 AnaptysBio plans to file a biologics license application (BLA) for Generalized pustular psoriasis with the US FDA in 2025
  • 03 Feb 2025 Imsidolimab licensed to Vanda Pharmaceuticals in World
  • 03 Feb 2025 Vanda Pharmaceuticals announces intention to submit MAA to Europe Union for Generalized pustular psoriasis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top